Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis

Multiple Sclerosis

Volumn 9, Issue 3, 2003, Pages 280-283

  Bowen, James D ^a   Maravilla, Kenneth ^b   Margolin, Solomon B ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Marnac Inc   (United States)

Author keywords

Cytokines; Multiple sclerosis; Progressive; Treatment

Indexed keywords

PIRFENIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISABILITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; HEALTH SURVEY; HUMAN; IRRITABILITY; MALE; MOBILIZATION; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OUTCOMES RESEARCH; PILOT STUDY; PNEUMONIA; POTENTIOMETRIC TITRATION; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; SEDATION; SIDE EFFECT; SLEEP DISORDER; VERTIGO;

ADULT; BRAIN; DISABILITY EVALUATION; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NERVOUS SYSTEM; PILOT PROJECTS; PYRIDONES; QUALITY OF LIFE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037645911     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458503ms907oa     Document Type: Article

References (22)

1. Lurton J, Trejo T, Narayanan AS, Raghu G. Pirfenidone inhibits the stimulatory effects of pro-fibrotic cytokines on human lung fibroblasts in vitro. Am J Resp Crit Care Med 1996; 153: A403.
2. Lee BS, Margolin SB, Nowak RA. Pirfenidone: A novel pharmacological agent that inhibits leiomyoma cell proliferation and collagen production. J Clin Endocrinol Metab 1998; 83: 213-23.
3. Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 2000; 24: 477-91.
4. Corbel M, Lanchou J, Germain N, Malledant Y et al. Modulation of airway remodeling-associated mediators by the anti-fibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice. Eur J Pharmacol 2001; 426: 113-21.
5. Waller J, Murphy GJ, Bicknell GR, Sandford R et al. Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats. Eur J Vasc Endovasc Surg 2002; 23: 234-40.
6. Zhang S, Shiels I, Ambler J, Taylor S. Pirfenidone reduces fibronectin synthesis by cultured human retinal pigment epithelial cells. Aust N Z J Ophthalmol 1998; 26: S74-S76.
7. Gurujeyalakshmi G, Hollinger M, Giri S. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999; 276: 311-18.
8. Cain W, Stuart RW, Lefkowitz DL, Starnes JD et al. Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharm 1998; 20: 685-95.
9. Waller JR, Murphy GJ, Metcalfe MS, Bicknell GR et al. Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury. Transplant Proc 2001; 33: 3816-18.
10. Kaneko M, Inoue H, Nakazawa R, Azuma N et al. Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down-regulation on cultured human synovial fibroblasts. Clin Exp Immunol 1998; 113: 72-76.
11. Misra H, Rabideau C. Pirfenidone inhibitis NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 2000; 204: 119-26.
12. Raghu G, Johnson W, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label phase II study. Am J Resp Crit Care Med 1999; 159: 1061-69.
13. Angulo P, MacCarty RL, Sylvestre PB, Jorgensen RA et al. Pirfenidone in the treatment of primary sclerosing cholangitis. Dig Dis Sci 2002; 47: 157-61.
14. Mesa R, Tefferi A, Elliott MA, Hoagland HC et al. A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 114: 111-13.
15. To Y, Sano Y, Sekiya T, Ogawa C et al. Successful treatment of steroid-resistant bronchiolitis obliterans - Organizing pneumonia with orally administered cyclosporin and pirfenidone. Nihon Kokyuki Gakkai Zasshi 2000; 38: 24-29.
16. Nowak R. Novel therapeutic strategies for leiomyomas: Targeting growth factors and their receptors. Environ Health Perspect 2000; 108: 849-53.
17. Walker J, Margolin S. Pirfenidone for chronic progressive multiple sclerosis. Mult Scler 2001; 7: 305-12.
18. Poser C, Paty DW, Scheinberg L, McDonald WI et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227.
19. Kurtzke J. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
20. Sipe JC, Knobler RL, Braheny SL, Rice GP et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984; 34: 1368-72.
21. Hauser S, Dawson DM, Lehrich JR, Beal MF et al. Intensive immunosuppression in progressive multiple sclerosis: A randomized three-arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983; 308: 173-80.
22. Goodkin D, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: Improving assessment sensitivity with box and block and nine-hole peg tests. Arch Phys Med Rehabil 1988; 69: 850-54.